

RECEIVED  
APR 03 2002  
TECH CENTER 1600/2900  
OIP E JCT 144  
FEB 07 2002  
PATENT & TRADEMARK OFFICE

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Filippo Belardelli, et al.) Re: Information Disclosure  
Statement  
Serial No.: 09/845,042 ) Group: 1636  
Filed: April 27, 2001 ) Examiner: unknown  
For: "METHOD FOR GENERATING HIGHLY ) Our Ref: B-4161 618742-8  
ACTIVE HUMAN DENDRITIC CELLS )  
FROM MONOCYTES" ) Date: February 1, 2002

1636  
A  
P#8

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

RECEIVED  
FEB 13 2002  
TECH CENTER 1600/2900

Sir:

In accordance with the Applicants' duty to disclose information which may be material to the examination of this application, the undersigned respectfully requests that the Examiner consider on the merits the documents listed on the enclosed Form PTO-1449 (modified) before issuing the first Office Action on the merits. We are enclosing herewith a copy of each document listed on the enclosed Form PTO-1449 (modified).

The filing of this Information Disclosure Statement (IDS) shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The Applicants believe that this IDS is being submitted before the issuance of a first Office Action on the merits and before the issuance of a Final Rejection or Notice of Allowance. Therefore, no official fees should be due; and this IDS should be considered on the merits. If this IDS is being submitted after the issuance of the first Office Action on the merits and before the issuance of a Final Rejection or Notice of Allowance, then the Commissioner is authorized to charge Deposit Account No. 12-0415 \$180.00 (or any other required amount), which is the fee set forth in 37 C.F.R. § 1.97(c); and this IDS should be fully considered on the

09845042  
02/11/2002 NHOAHM1 00000100 120415  
180.00 CR

Adjustment date: 07/24/2002 SDIRETA1  
02/11/2002 NHOAHM1 00000100 120415 09845042  
01 FC:126 180.00 CR


Information Disclosure Statement  
USSN 09/845,042  
February 1, 2002  
Page 2

merits, in accordance with 37 C.F.R. § 1.97(d). If this IDS is being submitted after the issuance of a Final Rejection or Notice of Allowance, then the Commissioner is not authorized to charge \$180.00 to Deposit Account No. 12-0415.


The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

The person making this statement is the practitioner who signs below on the basis of information supplied by an individual associated with the filing and prosecution of this application (37 C.F.R. § 1.56(c)) and on the basis of information in the practitioner's file.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to the "Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231", on February 1, 2002 by Suzanne Johnston.



Respectfully submitted,



John Palmer  
Attorney for Applicant  
Reg. No. 36,885

LADAS & PARRY  
5670 Wilshire Boulevard  
Suite 2100  
Los Angeles, CA 90036  
(323) 934-2300

Enclosures: Form PTO-1449 (modified) (4 pages)  
A copy of each document that is listed on Form  
PTO-1449 (modified)

Information Disclosure Statement  
 USSN 09/845,042  
 February 1, 2002  
 Page 3

RECEIVED  
 FEB 13 2002  
 TECH CENTER 1600/2900

Form PTO-1449 (Modified) Page 1 of 4	ATTY DOCKET NO. B-4161 618742-8	U.S. SERIAL NO. 09/845,042
LIST OF PATENTS AND PUBLICATIONS STATEMENT	APPLICANT Filippo Belardelli, et al.	
	FILING DATE April 27, 2001	GROUP 1636

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE or 102(e) DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Hart, D.N.J., "Dendritic Cells: Unique Leukocyte Populations Which Control the Primary Immune Response," <i>Blood</i> , Vol. 90, No. 9, pp. 3245-3287 (1997).
	Banchereau, J. and R.M. Steinman, "Dendritic cells and the control of immunity," <i>Nature</i> , Vol. 392, pp. 245-252 (1998).
	Bell, D., et al., "Dendritic Cells," <i>Adv. in Immunol.</i> , Vol. 72, pp. 255-324 (1999).
	Cella, M., et al., "Origin, maturation and antigen presenting function of dendritic cells," <i>Curr. Opin. Immunol.</i> , Vol. 9, pp. 10-16 (1997).
	Jonuleit, H., et al., "Induction of IL-15 Messenger RNA and Protein in Human Blood-Derived Dendritic Cells: A Role for IL-15 in Attraction of T Cells," <i>Journ. of Immunol.</i> , Vol. 158, pp. 2610-2615 (1997).
	Kuniyoshi, J.S., et al., "Dendritic Cell Secretion of IL-15 Is Induced by Recombinant huCD40LT and Augments the Stimulation of Antigen-Specific Cytolytic T Cells," <i>Cellular Immunology</i> , Vol. 193, pp. 48-58 (1999).

<u>EXAMINER</u>	<u>DATE CONSIDERED</u>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement  
 USSN 09/845,042  
 February 1, 2002  
 Page 4

**RECEIVED**  
 FEB 13 2002  
 TECH CENTER 1600/2900

<b>Form PTO-1449 (Modified)</b> <b>Page 2 of 4</b>	<b>ATTY DOCKET NO.</b> B-4161 618742-8	<b>U.S. SERIAL NO.</b> 09/845,042
<b>LIST OF PATENTS AND PUBLICATIONS STATEMENT</b>	<b>APPLICANT</b> Filippo Belardelli, et al.	
	<b>FILING DATE</b> April 27, 2001	<b>GROUP</b> 1636

**OTHER DOCUMENTS (cont.) (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Vella, A.T., et al., "Cytokine-induced survival of activated T cells in vitro and in vivo," <i>Proc Natl Acad Sci U.S.A.</i> , Vol. 95, No. 7, pp. 3810-3815 (1998).
	Borger, P., "Interleukin-15 differentially enhances the expression of interferon- $\gamma$ and interleukin-4 in activated human (CD4+) T lymphocytes," <i>Immunology</i> , Vol. 96, pp. 207-214 (1999).
	Avice, M., et al., "IL-15 Promotes IL-12 Production by Human Monocytes Via T Cell-Dependent Contact and May Contribute to IL-12-Mediated IFN- $\gamma$ Secretion by CD4+ T Cells in the Absence of TCR Ligation," <i>Journ. of Immunol.</i> , Vol. 161, pp. 3408-3415 (1998).
	Sallusto, F., et al., "The Role of Chemokine Receptors in Primary, Effector, and Memory Immune Responses," <i>Annu. Rev. Immunol.</i> , Vol. 18, pp. 593-620 (2000).
	Dieu-Nosjean, M.C., et al., "Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines," <i>Journ. of Leukocyte Biology</i> , Vol. 66, pp. 252-262 (1999).
	Sozzani, S., et al., "Chemokines and Dendritic Cell Traffic," <i>Journ. of Clinical Immunol.</i> , Vol. 20, No. 3, pp. 151-160 (2000).
	Schall, T.J. and K.B. Bacon, "Chemokines, leukocyte trafficking, and inflammation," <i>Curr. Opin. in Immunol.</i> , Vol. 6, pp. 865-873 (1994).
	Sozzani, S., et al., "Migration of Dendritic Cells in Response to Formyl Peptides, C5a, and a Distinct Set of Chemokines," <i>Journ. of Immunol.</i> , Vol. 155, pp. 3292-3295 (1995).

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement  
 USSN 09/845,042  
 February 1, 2002  
 Page 5

RECEIVED  
 FEB 13 2002  
 TECH CENTER 1600/2900

Form PTO-1449 (Modified) Page 3 of 4	ATTY DOCKET NO. B-4161 618742-8	U.S. SERIAL NO. 09/845,042
LIST OF PATENTS AND PUBLICATIONS STATEMENT	APPLICANT Filippo Belardelli, et al.	
	FILING DATE April 27, 2001	GROUP 1636

**OTHER DOCUMENTS (cont.) (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Sozzani, S., "Differential Regulation of Chemokine Receptors During Dendritic Cell Maturation: A Model for Their Trafficking Properties," <i>Journ. of Immunol.</i> , Vol. 161, pp. 1083-1086 (1998).
	Qin, S., et al., "The Chemokine Receptors CXCR3 and CCR5 Mark Subsets of T Cells Associated with Certain Inflammatory Reactions," <i>J. Clin. Invest.</i> , Vol. 101, No. 4, pp. 746-754 (1998).
	Liu, M.T., et al., "The T Cell Chemoattractant IFN-Inducible Protein 10 Is Essential in Host Defense Against Viral-Induced Neurologic Disease," <i>Journ. of Immunol.</i> , Vol. 165, pp. 2328-2330 (2000).
	Andrew, D.P., et al., "STCP-1 (MDC) CC Chemokine Acts Specifically on Chronically Activated Th2 Lymphocytes and Is Produced by Monocytes on Stimulation with Th2 Cytokines IL-4 and IL-13," <i>Journ. of Immunol.</i> , Vol. 161, pp. 5027-5038 (1998).
	Sallusto, F. and A. Lanzavecchia, "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor $\alpha$ ," <i>J. Exp. Med.</i> , Vol. 179, pp. 1109-1118 (1994).
	Romani, N., et al., "Proliferating Dendritic Cell Progenitors in Human Blood," <i>J. Exp. Med.</i> , Vol. 180, pp. 83-93 (1994).
	Caux, C., et al., "GM-CSF and TNF- $\alpha$ cooperate in the generation of dendritic Langerhans cells," <i>Nature</i> , Vol. 360, pp. 258-261 (1992).
	Reddy, A., et al., "A Monocyte Conditioned Medium Is More Effective Than Defined Cytokines in Mediating the Terminal Maturation of Human Dendritic Cells," <i>Blood</i> , Vol. 90, No. 9, pp. 3640-3646 (1997).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement  
 USSN 09/845,042  
 February 1, 2002  
 Page 6

**RECEIVED**  
 FEB 13 2002  
 TECH CENTER 1600/2900

<b>Form PTO-1449 (Modified)</b> <b>Page 4 of 4</b>	<b>ATTY DOCKET NO.</b> B-4161 618742-8	<b>U.S. SERIAL NO.</b> 09/845,042
<b>LIST OF PATENTS AND PUBLICATIONS STATEMENT</b>	<b>APPLICANT</b> Filippo Belardelli, et al.	
	<b>FILING DATE</b> April 27, 2001	<b>GROUP</b> 1636

**OTHER DOCUMENTS (cont.) (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Goxe, B., et al., "Monocyte-derived dendritic cells: development of a cellular processor for clinical applications," <i>Res. Immunol.</i> , Vol. 149, pp. 643-646 (1998).
	Santini, S.M., et al., "Type I Interferon as a Powerful Adjuvant for Monocyte-derived Dendritic Cell Development and Activity In Vitro and in Hu-PBL-SCID Mice," <i>J. Exp. Med.</i> , Vol. 191, No. 10, pp. 1777-1788 (2000).
	Forster, R., et al., "CCR7 Coordinates the Primary Immune Response by Establishing Functional Microenvironments in Secondary Lymphoid Organs," <i>Cell</i> , Vol. 99, pp. 23-33 (1999).
	Rossio, J.L., et al., "Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins," <i>Journ. of Virology</i> , Vol. 72, No. 10, pp. 7792-8001 (1998).
	Mosier, D.E., et al., "Transfer of a functional human immune system to mice with severe combined immunodeficiency," <i>Nature</i> , Vol. 335, pp. 256-259 (1988).
	Coccia, M.A., et al., "High Titer, Prostate Specific Antigen-Specific Human IgG Production by hu-PBL-SCID Mice Immunized with Antigen-Mouse IgG2a Complex-Pulsed Autologous Dendritic Cells," <i>Journ. of Immunol.</i> , Vol. 161, pp. 5772-5780 (1998).
	Mosier, D.E., et al., "Studies of HIV Infection and the Development of Epstein-Barr Virus-Related B Cell Lymphomas Following Transfer of Human Lymphocytes to Mice With Severe Combined Immunodeficiency," <i>Current Topics in Microbiology and Immunology</i> , Vol. 152, pp. 195-199 (1989).
	Rowe, M., et al., "Epstein-Barr Virus (EBV)-associated Lymphoproliferative Disease in the SCID Mouse Model: Implications for the Pathogenesis of EBV-positive Lymphomas in Man," <i>J. Exp. Med.</i> , Vol. 173, pp. 147-158 (1991).

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.